Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Summer;17(2):162-174.

Medication-Induced Tardive Dyskinesia: A Review and Update

Affiliations
Review

Medication-Induced Tardive Dyskinesia: A Review and Update

Elyse M Cornett et al. Ochsner J. 2017 Summer.

Abstract

Background: Tardive dyskinesia (TD) is a movement disorder that causes involuntary, repetitive body movements and is commonly seen in patients who are on long-term treatment with antipsychotic medications. However, several other classes of medications with different mechanisms are also associated with TD.

Methods: We conducted a PubMed search using keywords and combined word searches that involved medication-induced TD, as well as agents that are associated with causing or are used to treat medication-induced TD. We attempted to include as many recent (publication date of 2015 and later) articles as possible.

Results: The reported incidence of TD seems to be reduced with the use of atypical antipsychotic drugs, yet the risk of developing TD remains with these medications. Furthermore, several other medication classes have a high prevalence of TD and yet are not commonly considered to be TD-inducing. This review highlights the need for a prevention-based focus of TD treatment that starts with a clinical consideration of pharmacologic choices related to each individual patient's history.

Conclusion: This review offers the information current as of 2016 on the pathophysiology, etiology, and epidemiology of TD, as well as the medications associated with TD, mechanisms of medication-induced TD, and treatments for medication-induced TD.

Keywords: Anti-dyskinesia agents; dyskinesias; dyskinesia–drug-induced; movement disorders; tardive dyskinesia.

PubMed Disclaimer

References

    1. Waln O, Jankovic J. . An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013. Jul 12;3. 10.7916/d88p5z71. - DOI - PMC - PubMed
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington, VA: American Psychiatric Association; 2013.
    1. Kulkarni SK, Naidu PS. . Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today (Barc). 2003. January; 39 1: 19- 49. - PubMed
    1. Jensen N, Oliveira JRM. . Basal ganglia vulnerability to oxidative stress. Front Neurosci. 2014. April 21; 8: 80 10.3389/fnins.2014.00080. - DOI - PMC - PubMed
    1. Martins MR, Petronilho FC, Gomes KM, Dal-Pizzol F, Streck EL, Quevedo J. . Antipsychotic-induced oxidative stress in rat brain. Neurotox Res. 2008. January; 13 1: 63- 69. - PubMed